JCEM case reports · 2026
Incidental endometrial cancer diagnosis during pre-IVF workup: fertility-sparing treatment and embryo preservation.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gayete-Lafuente Sonia, Mian Umar, Choong Elizabeth, Guijarro-Baude Lara, Barad David, Gleicher Norbert
Аннотация
We report the incidental diagnosis of endometrial cancer in a 42-year-old nulliparous woman undergoing routine fertility workup. During pre-in vitro fertilization (IVF) saline hysterosonography (HSN), a small (<1 cm) endometrial polyp at the fundus was identified and removed hysteroscopically. Initial histologic examination performed outside the United States demonstrated a grade 2 endometrioid carcinoma. The hysteroscopic pathology slides were subsequently reviewed in the United States, and the diagnosis was revised to grade 1, stage IA endometrioid carcinoma confined to the endometrium. Staging magnetic resonance imaging showed no myometrial invasion or metastatic disease, supporting a fertility-sparing management approach. Before initiating high-dose progestin therapy, the patient underwent fertility-preserving ovarian stimulation with a letrozole-based gonadotropin-releasing hormone antagonist protocol. This cycle yielded 4 embryos for cryopreservation. Had she proceeded with her planned IVF cycle before endometrial lesion was assessed, ovarian stimulation might have accelerated an undiagnosed estrogen-dependent malignancy. This case underscores the value of comprehensive pre-IVF diagnostic evaluation, through which incidentally detected early-stage endometrial carcinoma can be identified before ovarian stimulation and embryo transfer. It also highlights a potential role for fertility preservation in selected reproductive-aged patients and emphasizes the importance of guideline-based fertility-sparing management in estrogen-dependent gynecologic cancers.